CAMRYN DAVIS: Open Payments
NPI 1518693746 · DETROIT, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$706 in 42 payments from 12 companies in 2025. Trend: 2023 $116 · 2024 $259 · 2025 $706
Food & beverage: $706
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $136 |
| Novo Nordisk Inc | 6 | $95 |
| ABBVIE INC. | 4 | $85 |
| Otsuka America Pharmaceutical, Inc. | 4 | $85 |
| Xeris Pharmaceuticals, Inc. | 4 | $62 |
| GlaxoSmithKline, LLC. | 3 | $52 |
| Inspire Medical Systems, Inc. | 2 | $51 |
| AstraZeneca Pharmaceuticals LP | 3 | $48 |
| Exact Sciences Corporation | 2 | $30 |
| Ascensia Diabetes Care Us Inc. | 1 | $22 |
Products named: CAPLYTA, REXULTI, VRAYLAR, TRELEGY ELLIPTA, INSPIRE, AIRSUPRA, RECORLEV, Wegovy.
Industry payments across MI — which companies pay providers there.
